DNA Diagnostics Market Report 2026

The dna diagnostics market size has grown rapidly in recent years. It will grow from $25.62 billion in 2025 to $28.37 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to advances in molecular biology, early cancer diagnostics adoption, infectious disease burden, laboratory automation growth, declining sequencing costs.

The dna diagnostics market size is expected to see strong growth in the next few years. It will grow to $40.11 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to precision medicine expansion, ai-driven diagnostics, population genetic screening, regulatory support for molecular tests, clinical genomics adoption. Major trends in the forecast period include rising adoption of genetic-based disease diagnosis, increased use of pcr and sequencing technologies, expansion of oncology and infectious disease testing, growth of personalized diagnostic solutions, integration of bioinformatics and data analysis tools.

The increasing prevalence of genetic disorders is expected to drive the growth of the DNA diagnostics market in the coming years. Genetic disorders are medical conditions resulting from abnormalities in an individual’s DNA, including single-gene mutations, chromosomal irregularities, or multifactorial genetic influences. The rise in genetic disorder cases is attributed to factors such as improved diagnostic capabilities, broader adoption of genetic testing, environmental influences, and consanguinity patterns that increase the likelihood of inherited conditions. The DNA diagnostics market supports this growth by enabling accurate identification of genetic abnormalities through DNA analysis, supporting early diagnosis, personalized treatment approaches, and informed reproductive decision-making. For example, in February 2023, the World Health Organization (WHO), a Switzerland-based specialized United Nations agency for global public health, reported that congenital disorders account for an estimated 240,000 newborn deaths within the first 28 days of life annually, along with an additional 170,000 deaths among children aged one month to five years. Consequently, the rising prevalence of genetic disorders is fueling the growth of the DNA diagnostics market.

Companies operating in the DNA diagnostics market are increasingly focused on developing advanced solutions such as liquid biopsy tests to enable earlier cancer detection, enhance treatment decision-making, and improve patient outcomes. A liquid biopsy is a minimally invasive diagnostic approach that examines biomarkers such as circulating tumor cells, cell-free DNA, or exosomes present in the bloodstream, offering insights into tumor genetics without requiring surgical tissue biopsies. For instance, in May 2023, Laboratory Corporation, a US-based healthcare diagnostics company, introduced LabCorp Plasma Focus, a liquid biopsy test designed to identify targeted therapy options for patients with advanced or metastatic solid tumors. The test sequences circulating cell-free DNA released by tumor cells, enabling oncologists to personalize treatment strategies and enhance the precision of cancer care.

In March 2024, Bayer AG, a Germany-based pharmaceutical company, partnered with Thermo Fisher Scientific Inc. to develop next-generation sequencing (NGS)-based companion diagnostic (CDx) assays. Through this collaboration, Bayer and Thermo Fisher aim to combine Bayer’s precision oncology therapies with Thermo Fisher’s Oncomine Dx Express Test on the Ion Torrent Genexus Dx System to deliver decentralized and rapid genomic testing, with turnaround times as short as 24 hours. This initiative is intended to improve patient access to appropriate targeted therapies and advance precision cancer care. Thermo Fisher Scientific Inc. is a US-based life sciences company providing a broad range of DNA diagnostics solutions.

Major companies operating in the dna diagnostics market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton, Dickinson and Company, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies, Illumina Inc, PerkinElmer Inc, bioMérieux SA, Beckman Coulter Inc, Sysmex Corporation, Bio-Rad Laboratories Inc, QIAGEN N.V., Natera Inc, Myriad Genetics Inc., BGI Genomics Co. Ltd., Cepheid, NeoGenomics Laboratories Inc, 23andMe Holding Co, Ambry Genetics Corporation, Biocartis SA, CENTOGENE N.V., Veritas Genetics.

North America was the largest region in the DNA diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dna diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dna diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the dna diagnostics market by increasing costs of imported reagents, sequencing instruments, and analytical software systems. Diagnostic centers in developed regions are most affected due to technology imports, while emerging markets face slower adoption. These tariffs increase testing costs. However, they promote domestic production of reagents and diagnostic instruments.

The dna diagnostics market research report is one of a series of new reports that provides dna diagnostics market statistics, including dna diagnostics industry global market size, regional shares, competitors with a dna diagnostics market share, detailed dna diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the dna diagnostics industry. This dna diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Deoxyribonucleic acid (DNA) diagnostics involves the use of genetic testing techniques to analyze DNA, RNA, and proteins for medical, forensic, or research applications. These tests offer insights into genetic predispositions, disease susceptibility, and ancestry. DNA diagnostics has transformed medicine and genetics by providing powerful tools for understanding, diagnosing, and managing health conditions.

The types of products in DNA diagnostics include instruments, reagents, software, and services. An instrument refers to specialized equipment or machinery used to perform the analysis of DNA samples. The technologies employed include polymerase chain reaction, microarray, in-situ hybridization, sequencing technologies, and mass spectrometry. These are used across various applications such as oncology, infectious disease treatment, myogenic disorder treatment, clinical diagnostic confirmation, prenatal and pre-implantation testing, and others. The end users include point-of-care settings, diagnostic centers, and self-testing or over-the-counter (OTC) users.

The DNA diagnostics market consists of revenues earned by entities by providing services such as ancestry testing, paternity or maternity testing, genetic health risk assessment, carrier testing, pharmacogenetic testing, forensic DNA analysis, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The DNA diagnostics market also includes sales of DNA extraction kits, thermal cyclers or polymerase chain reaction machines, DNA sequencers, gel electrophoresis systems, DNA microarrays, automated liquid handling systems, and DNA storage and preservation kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.